Debra A. Goff

Debra A. Goff

Auto-generated profile, based on publicly available information

Debra A. Goff

The Ohio State University Wexner Medical Center, Department of Pharmacy , Columbus, Ohio

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KBKarri A. Bauer
Karri A. Bauer
JWJessica E. West
Jessica E. West
JBJoan‐Miquel Balada‐Llasat
Joan‐Miquel Balada‐Llasat
PPPreeti Pancholi
Preeti Pancholi
KSKurt B. Stevenson
Kurt B. Stevenson
DGDebra A. Goff
Debra A. Goff
Rapid organism detection of Staphylococcus aureus bacteremia and communication to clinicians expedites antibiotic optimization. We evaluated clinical and economic outcomes of a rapid polymerase chain reaction methicillin-resistant S. aureus/S. aureusblood culture test (rPCR). This single-center study compared inpatients with S. aureusbacteremia admitted from 1 September 2008 through 31 December 2008 (pre-rPCR) and those admitted from 10 March 2009 through 30 June 2009 (post-rPCR). An infectious diseases pharmacist was contacted with results of the rPCR; effective antibiotics and an infectious diseases consult were recommended. Multivariable regression assessed clinical and economic outcomes of the 156 patients. Mean time to switch from empiric vancomycin to cefazolin or nafcillin in patients with methicillin-susceptible S. aureusbacteremia was 1.7 days shorter post-rPCR (P = .002). In the post-rPCR methicillin-susceptible and methicillin-resistant S. aureusgroups, the mean length of stay was 6.2 days shorter (P = .07) and the mean hospital costs were $21,387 less (P = .02). rPCR allows rapid differentiation of S. aureusbacteremia, enabling timely, effective therapy and is associated with decreased length of stay and health care costs.

15 October 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KBKarri A. Bauer
Karri A. Bauer
KPKatherine K. Perez
Katherine K. Perez
GFGraeme N. Forrest
Graeme N. Forrest
DGDebra A. Goff
Debra A. Goff
Rapid microbiologic tests provide opportunities for antimicrobial stewardship programs to improve antimicrobial use and clinical and economic outcomes. Standard techniques for identification of organisms require at least 48–72 hours for final results, compared with rapid diagnostic tests that provide final organism identification within hours of growth. Importantly, rapid microbiologic tests are considered “game changers” and represent a significant advancement in the management of infectious diseases. This review focuses on currently available rapid diagnostic tests and, importantly, the impact of rapid testing in combination with antimicrobial stewardship on patient outcomes.

1 February 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
DGDebra A Goff
Debra A Goff
RKRavina Kullar
Ravina Kullar
EGEllie J C Goldstein
Ellie J C Goldstein
MGMark Gilchrist
Mark Gilchrist
DNDilip Nathwani
Dilip Nathwani
MMMarc Mendelson
Marc Mendelson

1 July 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
KBKarri A. Bauer
Karri A. Bauer
JWJessica E. West
Jessica E. West
JOJames M. O'Brien
James M. O'Brien
DGDebra A. Goff
Debra A. Goff
In an era of escalating resistance and a lack of new antimicrobial discovery, stewardship programs must utilize knowledge of pharmacodynamics to achieve maximal exposure in the treatment of Pseudomonas aeruginosa infections. We evaluated the clinical and economic outcomes associated with extended-infusion cefepime in the treatment of P. aeruginosa infections. This single-center study compared inpatients who received cefepime for bacteremia and/or pneumonia admitted from 1 January 2008 through 30 June 2010 (a 30-min infusion of 2 g every 8 h) to those admitted from 1 July 2010 through 31 May 2011 (a 4-h infusion of 2 g every 8 h). The overall mortality was significantly lower in the group that received extended-infusion treatment (20% versus 3%; P = 0.03). The mean length of stay was 3.5 days less for patients who received extended infusion ( P = 0.36), and for patients admitted to the intensive care unit the mean length of stay was significantly less in the extended-infusion group (18.5 days versus 8 days; P = 0.04). Hospital costs were $23,183 less per patient, favoring the extended-infusion treatment group ( P = 0.13). We conclude that extended-infusion treatment with cefepime provides increased clinical and economic benefits in the treatment of invasive P. aeruginosa infections.

21 May 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DGDebra A. Goff
Debra A. Goff
KBKarri A. Bauer
Karri A. Bauer
ERErica E. Reed
Erica E. Reed
KSKurt B. Stevenson
Kurt B. Stevenson
JTJeremy J. Taylor
Jeremy J. Taylor
JWJessica E. West
Jessica E. West
A new antimicrobial stewardship program can be overwhelmed at the breadth of interventions and education required to conduct a successful program. The expression “low-hanging fruit,” in reference to stewardship, refers to selecting the most obtainable targets rather than confronting more complicated management issues. These targets include intravenous-to-oral conversions, batching of intravenous antimicrobials, therapeutic substitutions, and formulary restriction. These strategies require fewer resources and less effort than other stewardship activities; however, they are applicable to a variety of healthcare settings, including limited-resource hospitals, and have demonstrated significant financial savings. Our stewardship program found that staged and systematic interventions that focus on obvious areas of need, that is, low hanging fruit, provided early successes in our expanded program with a substantial cumulative cost savings of $832 590.

20 September 2020 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
DGDebra A. Goff
Debra A. Goff
Diane Ashiru-OredopeDiane Ashiru-Oredope
Diane Ashiru-Oredope
KCKelly A. Cairns
Kelly A. Cairns
KEKhalid Eljaaly
Khalid Eljaaly
TGTimothy P. Gauthier
Timothy P. Gauthier
NSNatalie Schellack
Natalie Schellack
Throughout the SARS‐CoV‐2 (COVID‐19) global pandemic, pharmacists were rarely mentioned as essential frontline health care providers by the news media, the public, or politicians. Around the world, pharmacists are working on the frontlines of health care every day providing essential health care services during the pandemic. Pharmacists are medication experts providing patient care in a variety of settings including hospitals, clinics, community pharmacies, long‐term care, physician offices, and national and public health. In this paper, we describe how pharmacists from high and low‐middle income countries contributed to essential patient care and well‐being of the public during the COVID‐19 pandemic. While the news media, the public, and politicians often overlooked pharmacists as essential frontline health care providers, we hope that this list of contributions by pharmacists from nine countries in this article can help to change this perspective.